You are about to leave Helsinn's Corporate US Website.

Please click 'Continue to external site' if you want to continue.

News

News

Helsinn Group and EISAI announce FDA acceptance of New Drug application for investigational compound netupitant 300 mg + palonestron 0.50 mg (NEPA)

Lugano, Switzerland and Woodcliff Lake, NJ, USA , December 9, 201 3 –  Helsinn Group and Eisai Inc. today announced that the U .S. Food and Drug Administration (FDA) accepted for review the submission of the New Drug Application (NDA) for the investigation al oral fixed- dose combination capsule of netupitant 300 mg + palonosetron 0.50 mg (N E PA) for prevention o f acute and delayed ch emotherapy – induced nausea and vomiting (CINV) following both highly and moderately emetogenic chemotherapy.